After Makary: What the FDA's Leadership Vacuum Means for Drug Development

On May 12, 2026, Marty Makary resigned as commissioner of the Food and Drug Administration, ending one of the most turbulent tenures in the agency's modern history. President Trump confirmed the departure at a meeting with reporters, offering a characteristically ambiguous send-off: "He was having some difficulty," Trump said, "but he's going to go on and he's going to do well." Kyle Diamantas, previously the FDA's deputy commissioner for food, will serve as acting commissioner while the administration searches for a permanent replacement.

The resignation lands at a particularly sensitive moment for the pharmaceutical and biotechnology industries. After years of pipeline rebuilding, record IPO activity, and a wave of transformative approvals, the sector had been counting on regulatory stability to sustain its momentum. Instead, it now faces yet another leadership transition at the agency that controls the fate of every drug, device, and biologic seeking to reach American patients.

A Tenure Defined by Contradiction

Makary arrived at the FDA in early 2025 with genuine credibility. A prolific Johns Hopkins surgeon and medical author, he had spent years critiquing what he called scientific "groupthink" and advocating for a more flexible, patient-centered regulatory approach. His confirmation hearing was smooth. His early agenda was ambitious: a new framework for approving ultra-rare disease therapies, a push to require only one pivotal clinical trial instead of the traditional two, expanded use of AI in drug reviews, and a novel national priority voucher program designed to accelerate development of strategically important medicines.

On paper, these were exactly the kinds of reforms the biotech industry had long requested. In practice, the execution was far messier. Multiple senior officials departed under his watch. Vinay Prasad, the outspoken head of the office overseeing vaccines and gene therapies, resigned twice. George Tidmarsh, tapped to lead the Center for Drug Evaluation and Research, left amid a conduct investigation. Richard Pazdur, a legendary figure in oncology regulation, announced retirement plans within weeks of being asked to lead CDER, citing tensions with Makary and concerns about the pace of change. The revolving door at the agency's highest levels created a perception problem that no policy initiative could fully offset.

The Cost of Unpredictability

For the companies that depend on the FDA, the deeper damage was not any single decision but the erosion of predictability. Stifel analyst Paul Matteis captured the sentiment bluntly late last year: "FDA, and our ability to predict the FDA, is about as uncertain as it's been in the past decade or longer." That uncertainty has real financial consequences. Drug development timelines are built around regulatory assumptions. When those assumptions become unreliable, capital allocation decisions shift, clinical trial designs become more conservative, and smaller biotechs with limited runway face existential risk from unexpected review delays or surprise rejections.

The agency also drew fire from multiple political directions simultaneously, a sign of how difficult the commissioner role has become in the current environment. Anti-abortion groups were frustrated by Makary's handling of mifepristone. Trump reportedly pressured him to approve flavored vaping products. The biotech industry wanted organizational stability. Each constituency pulled in a different direction, and the result was an agency that appeared reactive rather than principled.

What Comes Next

The immediate question is whether Kyle Diamantas, a career official whose background is in food safety rather than drug regulation, can provide the steady hand the industry is asking for while a permanent nominee is identified and confirmed. Acting commissioners rarely make bold moves, which may itself be a form of stability. But the FDA's drug review calendar does not pause for leadership transitions. PDUFA deadlines will continue to arrive, advisory committee meetings will proceed, and companies awaiting approval decisions will be watching closely for any sign that the agency's direction is shifting again.

The longer-term question is what kind of FDA the Trump administration actually wants. Makary's reform agenda was not without merit, and some of his initiatives, particularly around accelerating reviews for rare diseases and integrating AI into regulatory science, reflected genuine needs. The challenge was that the institutional disruption required to implement those reforms outpaced the agency's capacity to absorb change without losing the scientific rigor that makes FDA approval meaningful in the first place.

A Sector That Needs Stability

The biotechnology industry is in a better place than it was two years ago. IPO windows have reopened, deal activity is accelerating, and clinical trial data across multiple therapeutic areas have been genuinely encouraging. But that recovery remains fragile. Investor confidence in biotech is partly a bet on the regulatory environment, and a predictable, science-driven FDA is one of the sector's most important structural assets.

John Crowley, head of the Biotechnology Innovation Organization, said it plainly after Pazdur's retirement announcement: "We need organizational strength and stability at the agency. It is time to right the ship." That call has not yet been answered. The next FDA commissioner will inherit an agency that is understaffed, politically exposed, and operating under a cloud of institutional uncertainty. Whoever takes the job will need to rebuild trust not just with the industry, but with the scientists and reviewers inside the agency whose expertise is the foundation of everything the FDA does.

Makary's departure is not the end of the story. It is, at best, the beginning of a reset. Whether that reset produces a more functional, more predictable FDA depends entirely on who comes next and whether the administration is willing to give them the space to lead.